Skip to content
Try Mental Wellness – Lifestyle
Author:
Solid Biosciences Inc.
Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia
October 26, 2026
Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026
October 20, 2026
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 1, 2026
Solid Biosciences to Participate at Upcoming Investor Conferences
September 2, 2026
Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 6, 2026
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 1, 2026
Solid Biosciences to Participate at Upcoming Investor Conferences
June 1, 2026
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
May 12, 2026
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
May 7, 2026
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 1, 2026
1
2
Next Page
→